Patents by Inventor Siang-Yo Lin

Siang-Yo Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210299270
    Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 30, 2021
    Applicants: Rutgers, The State University of New Jersey, Georgetown University
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
  • Publication number: 20210177985
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Applicants: Rutgers, The State University of New Jersey, Georgetown University
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20190358340
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 10376597
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: August 13, 2019
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20190151464
    Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: March 17, 2017
    Publication date: May 23, 2019
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
  • Publication number: 20180177889
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9849192
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E(MMAE) and monomethyl auristatin F(MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 26, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9682094
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: June 20, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Patent number: 9549993
    Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: January 24, 2017
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Michael Johnson
  • Publication number: 20160263244
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 15, 2016
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20160015728
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: August 26, 2015
    Publication date: January 21, 2016
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
  • Publication number: 20150250895
    Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 10, 2015
    Applicant: Georgetown University
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Michael Johnson
  • Publication number: 20120294800
    Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.
    Type: Application
    Filed: November 18, 2010
    Publication date: November 22, 2012
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin